ELVN Q4 2021 Earnings — Enliven Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ELVNEnliven Therapeutics, Inc.

$2B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$8M

Net Income

-$8M

EPS (Diluted)

$-2.18

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$113M

Total Liabilities

$6M

Stockholders' Equity

$107M

Cash & Equivalents

$110M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$8M	-$12M	+27.3%
Net Income	-$8M	-$12M	+27.1%